GLP-1s represent the biggest problem with the US healthcare system
GLP-1s represent the biggest problem with the US healthcare system
Last updated: 2026-02-10 05:39:13 ET
GLP-1s represent the biggest problem with the US healthcare system
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales s...
Walmart hits $1T market cap, PepsiCo CEO talks earnings beat and GLP-1 strategy
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficac...